Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Esophageal squamous cell carcinoma (ESCC) is a severe health threat, being a predominant subtype of esophageal cancer and contributing significantly to cancer-related mortality globally. Despite ...
A new study published in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer Center details a therapeutic vulnerability in patients with an aggressive subtype ...
Verzenio monotherapy provided clinical benefits to 33% of patients with HR-positive, HER2-negative breast cancer after prior CDK4/6 inhibitor therapy. The rAMBER study highlights Verzenio's potential ...
SAN ANTONIO — A machine learning model, which incorporates both clinical and genomic factors, helps predict which patients with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results